Par Drugs & Che.

Why is Par Drugs & Chemicals Ltd falling/rising?

As of 24-Aug, the stock price of Par Drugs & Chemicals Ltd is rising due to its net-debt-free status, increased profit after tax, and significant sales growth, indicating strong operational performance. However, declining investor participation may threaten the stock's upward momentum.

As of 24-Aug, the stock price of Par Drugs & Chemicals Ltd is rising, currently at 101.45, with a change of 0.12 (0.12%) upwards. This positive movement can be attributed to several factors. The company is net-debt free, which enhances its financial stability. Additionally, the profit after tax (PAT) for the first nine months is higher at Rs 10.36 crore, and net sales for the latest quarter have grown by 20.7% compared to the previous four-quarter average, reaching Rs 31.28 crore. The highest quarterly PBDIT at Rs 6.38 crore further indicates strong operational performance.<BR><BR>Moreover, the stock is trading at a fair valuation with a price-to-book value of 1.1, which is attractive compared to its peers' average historical valuations. Despite a modest year-to-date return of 0.19%, the stock has generated a return of 2.75% over the past year, aligning with a profit increase of 2.3%. These factors contribute to a favorable outlook for the stock, supporting its recent price rise. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 62.41% against the five-day average, which could pose a risk to sustained upward momentum.

Which are the latest news on Par Drugs & Che.?

Should I buy, sell or hold Par Drugs & Chemicals Ltd?

Who are in the management team of Par Drugs & Che.?

The management team of Par Drugs & Chemicals includes Chairman & Managing Director Falgun Vallabhbhai Savani, Executive Director & CEO Jigneshbhai Vallabhbhai Savani, and several other directors, both executive and independent, who guide the company's strategic direction and operations.

The management team of Par Drugs & Chemicals includes the following key members:<BR><BR>1. **Falgun Vallabhbhai Savani** - Chairman & Managing Director<BR>2. **Jigneshbhai Vallabhbhai Savani** - Executive Director & CEO<BR>3. **Ghanshayambhai Bhagvanbhai Savani** - Whole Time Director & Executive Director<BR>4. **Nayna Jignesh Savani** - Non-Executive Director<BR>5. **Krishna Mitulbhai Shah** - Independent Non-Executive Director<BR>6. **Kajal Chintanbhai Vaghani** - Independent Non-Executive Director<BR>7. **Pravin Manjibhai Bhayani** - Independent Non-Executive Director<BR>8. **Bintal Bhaveshkumar Shah** - Independent Non-Executive Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

What does Par Drugs & Che. do?

Par Drugs and Chemicals Ltd is a Micro Cap company in the Chemicals & Petrochemicals industry, reporting net sales of 31 Cr and a net profit of 5 Cr for June 2026. It has a market cap of INR 128 Cr, a P/E ratio of 8.00, and a return on equity of 12.94%.

Overview:<BR>Par Drugs and Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1999 as a Private Limited Company and later converted to a Public Limited Company in 2018. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 31 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 5 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 128 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00 <BR>Industry P/E: 44 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.37 <BR>Return on Equity: 12.94% <BR>Price to Book: 1.13 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Par Drugs & Che.?

Par Drugs & Che.'s peers include Mahickra Chem., Arvee Laborat., Indian Phosphate, and others. In terms of management risk, growth, and capital structure, Indian Phosphate and Paragon Fine perform well, while Par Drugs & Che. shows average management risk and growth, with a 1-year return of -1.61%.

Peers: The peers of Par Drugs & Che. are Mahickra Chem., Arvee Laborat., Indian Phosphate, Vital Chemtech, Jocil, Hindcon Chemical, Paragon Fine, Indian Emuls, Unilex Colour &C, and Nilachal Carbo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Phosphate and Paragon Fine, while Average management risk is found at Mahickra Chem., Jocil, Hindcon Chemical, and Par Drugs & Che. Below Average management risk is present at Arvee Laborat., Vital Chemtech, Unilex Colour &C, and Indian Emuls. Growth is Excellent at Indian Emuls, Below Average at Mahickra Chem., Arvee Laborat., Vital Chemtech, Jocil, Par Drugs & Che., Hindcon Chemical, and the rest, while Average growth is noted at Indian Phosphate and Paragon Fine. Capital Structure is Excellent at Indian Phosphate, Jocil, and Paragon Fine, Good at Arvee Laborat. and Hindcon Chemical, and Below Average at Mahickra Chem., Vital Chemtech, Unilex Colour &C, and Indian Emuls.<BR><BR>Return Snapshot: Mahickra Chem. has the highest 1-year return at 102.16%, while Indian Emuls has the lowest at -71.40%. Par Drugs & Che. has a 1-year return of -1.61%, which is significantly higher than Indian Emuls but lower than Mahickra Chem. Additionally, Hindcon Chemical, Indian Emuls, and Unilex Colour &C have negative six-month returns.

How big is Par Drugs & Che.?

As of 14th August, Par Drugs & Chemicals Ltd has a market capitalization of 124.40 Cr and reported net sales of 108.89 Cr and net profit of 14.49 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Par Drugs & Chemicals Ltd has a market capitalization of 124.40 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 108.89 Cr, while the sum of Net Profit for the same period is 14.49 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds amount to 98.97 Cr, and Total Assets are valued at 119.39 Cr.

Are Par Drugs & Chemicals Ltd latest results good or bad?

Par Drugs & Chemicals Ltd's latest results are concerning, with net sales dropping 33.16% to ₹19.61 crores and net profit falling 82.29% to ₹0.85 crores, indicating significant operational challenges and a decline in profitability. Investors should be cautious given these negative trends.

The latest results for Par Drugs & Chemicals Ltd indicate a significant downturn in performance, marking a challenging quarter for the company. In the March 2026 quarter, net sales dropped by 33.16% sequentially to ₹19.61 crores, which is the lowest quarterly sales figure in recent times. Additionally, net profit plummeted by 82.29% to just ₹0.85 crores, reflecting a sharp decline in profitability.<BR><BR>Operating margins also suffered, collapsing to 7.34% from 20.65% in the previous quarter, highlighting severe operational challenges. This deterioration stands in stark contrast to the company's strong nine-month performance, where net profit had surged by 153.36% earlier in the fiscal year.<BR><BR>Overall, the results are concerning, with multiple indicators pointing to operational difficulties and a decline in both revenue and profitability. Investors should be cautious as these trends raise questions about the company's ability to sustain its previous performance levels.

Is Par Drugs & Che. overvalued or undervalued?

As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. <BR><BR>In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present.

How has been the historical performance of Par Drugs & Che.?

Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.

Answer:<BR>The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantly to 119.39 Cr in Mar'25 from 60.12 Cr in Mar'20, with total liabilities also increasing to 119.39 Cr in Mar'25. Cash flow from operating activities was 16.00 Cr in Mar'25, although the net cash outflow was -9.00 Cr, down from a net inflow of 14.00 Cr in Mar'24. Overall, Par Drugs & Che. has shown robust growth in sales and profitability, despite some challenges in cash flow management.

What is the technical trend for Par Drugs & Che.?

As of May 12, 2025, Par Drugs & Che exhibits a mildly bearish trend overall, with mixed signals from key indicators such as a mildly bullish weekly MACD and bearish daily moving averages.

As of 12 May 2025, the technical trend for Par Drugs & Che has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory shows a mildly bullish trend on the weekly chart with no trend on the monthly. The OBV is mildly bearish weekly and mildly bullish monthly. Overall, the current stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands contributing to this view.

Who are the top shareholders of the Par Drugs & Che.?

The top shareholder of Par Drugs & Che. is Jignesh Vallabhbhai Savani, holding 21.88%. Other significant shareholders include Econo Trading And Investment Private Limited at 1.78% and individual investors with a combined stake of 20.3%.

The top shareholders of Par Drugs & Che. include the promoters, with Jignesh Vallabhbhai Savani holding the highest stake at 21.88%. There are no pledged promoter holdings, and the company is also held by two foreign institutional investors, although their combined stake is negligible at 0.0%. The highest public shareholder is Econo Trading And Investment Private Limited, which holds 1.78%. Additionally, individual investors collectively hold 20.3% of the company.

When is the next results date for Par Drugs & Che.?

No Upcoming Board Meetings

What is the bonus history of the Par Drugs & Che.?

Par Drugs & Chemicals Ltd issued a 1:1 bonus on April 27, 2021, with a record date of April 28, 2021, granting shareholders an additional share for each share held.

Par Drugs & Chemicals Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of April 27, 2021. The record date for this bonus was April 28, 2021. This means that shareholders on record as of that date received an additional share for every share they held.

Has Par Drugs & Che. declared dividend?

Par Drugs & Chemicals Ltd has declared a 12% dividend, amounting to 1.2 per share, with an ex-date of November 22, 2021. Despite the dividend declaration, the dividend yield is 0%, and the company has experienced significant volatility in total returns, ranging from -57.37% over 6 months to 495.27% over 5 years.

Par Drugs & Chemicals Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 22 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -57.37%, the dividend return was 0%, resulting in a total return of -57.37%.<BR><BR>In the 1-year period, the price return was -55.99%, the dividend return was 0%, resulting in a total return of -55.99%.<BR><BR>In the 2-year period, the price return was -52.72%, the dividend return was 0%, resulting in a total return of -52.72%.<BR><BR>In the 3-year period, the price return was -32.61%, the dividend return was 0%, resulting in a total return of -32.61%.<BR><BR>In the 4-year period, the price return was 51.47%, the dividend return was 1.31%, resulting in a total return of 52.78%.<BR><BR>In the 5-year period, the price return was 490.29%, the dividend return was 4.98%, resulting in a total return of 495.27%.<BR><BR>Overall, while Par Drugs & Chemicals Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show significant volatility, with negative returns in the shorter terms and substantial positive returns over the longer term, particularly in the 5-year period.